Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 13/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9888206 | 1.00 | ALK (0.51) | ALKPDPK1PAK4PAK1 | |
| SCHEMBL9888053 | 1.00 | ALK (0.51) | ALKPDPK1PAK4PAK1 | |
| SCHEMBL15253693 | 0.90 | ALK (0.51) | ALKPDPK1PAK4PAK1 | |
| SCHEMBL9276750 | 0.90 | ALK (0.51) | ALKPDPK1PAK4PAK1 | |
| SCHEMBL15253610 | 0.90 | ALK (0.51) | ALKPDPK1PAK4PAK1 | |
| SCHEMBL9887877 | 0.89 | ALK (0.54) | ALKPDPK1 | |
| SCHEMBL15257743 | 0.89 | ALK (0.54) | ALKPDPK1 | |
| SCHEMBL9887929 | 0.86 | ALK (0.48) | ALKPDPK1PAK4PAK1 | |
| SCHEMBL9888207 | 0.84 | ALK (0.47) | ALKPDPK1 | |
| SCHEMBL9887939 | 0.82 | ALK (0.54) | ALKPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | US | claimed |
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012072200-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | ALK 1314/4885PDPK1 5/4885PAK4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.